Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma

Journal of Clinical Oncology

Volumn 30, Issue 20, 2012, Pages 2509-2515

  Kindler, Hedy L ^a   Karrison, Theodore G ^a   Gandara, David R ^c   Lu, Charles ^f   Krug, Lee M ^g   Stevenson, James P ^h   Jänne, Pasi A ⁱ   Quinn, David I ^d   Koczywas, Marianna N ^e   Brahmer, Julie R ^j   Albain, Kathy S ^b   Taber, David A ^l   Armato III, Samuel G ^a   Vogelzang, Nicholas J ^a   Chen, Helen X ^k   Stadler, Walter M ^a   Vokes, Everett E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k NATIONAL CANCER INSTITUTE   (United States)

^l Northern Indiana Cancer Research Consortium   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CISPLATIN; GEMCITABINE; PLACEBO; VASCULOTROPIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EPISTAXIS; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; INFECTION WITHOUT NEUTROPENIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERFORATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; VEIN THROMBOSIS; VISCERAL PERFORATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; PLACEBOS; PLEURAL NEOPLASMS;

EID: 84864055587     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.5869     Document Type: Article

References (42)

1. Campbell NP, Kindler HL: Update on malignant pleural mesothelioma. Semin Respir Crit Care Med 32:102-110, 2011
2. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644, 2003 (Pubitemid 46606305)
3. Kindler HL, van Meerbeeck JP: The role of gemcitabine in the treatment of malignant mesothelioma. Semin Oncol 29:70-76, 2002 (Pubitemid 34163537)
4. Lee CW, Murray N, Anderson H, et al: Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: A review of practice in British Columbia. Lung Cancer 64:308-313, 2009
5. Byrne MJ Davidson JA, Musk AW, et al: Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study. J Clin Oncol 17:25-30, 1999 (Pubitemid 29022374)
6. van Haarst JM, Baas P, Manegold CH, et al: Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 86:342-345, 2002 (Pubitemid 34187648)
7. Nowak AK, Byrne MJ, Williamson R, et al: A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 87:491-496, 2002
8. Castagneto B, Zai S, Dongiovanni D, et al: Cisplatin and gemcitabine in malignant pleural mesothelioma: A phase II study. Am J Clin Oncol 28:223-226, 2005 (Pubitemid 40800471)
9. Kalmadi SR, Rankin C, Kraut MJ, et al: Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: A phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 60:259-263, 2008 (Pubitemid 351609140)
10. Utkan G, Buyukcelik A, Yalcin B, et al: Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma. Lung Cancer 53:367-374, 2006 (Pubitemid 44192595)
11. Dowell JE, Kindler HL: Antiangiogenic therapies for mesothelioma. Hematol Oncol Clin North Am 19:1137-1145, 2005 (Pubitemid 41736047)
12. Ohta Y, Shridhar V, Bright RK, et al: VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 81:54-61, 1999 (Pubitemid 29415491)
13. Strizzi L, Catalano A, Vianale G, et al: Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193:468-475, 2001 (Pubitemid 32266815)
14. Linder C, Linder S, Munck-Wikland E, et al: Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res 18:2063-2068, 1998 (Pubitemid 28344873)
15. Garland LL, Chansky K, Wozniak A, et al: SWOG S0509: A phase II study of novel oral antiangiogenic agent AZD2171 (NSC-732208) in malignant pleural mesothelioma. J Clin Oncol 27:384s, 2009 (suppl 15S; abstr 7511)
16. Dubey S, Janne PA, Krug L, et al: Phase II study of sorafenib in malignant mesothelioma: Results of Cancer and Leukemia Group B 30307. J Thorac Oncol 5:1655-1661, 2010
17. Nowak AK, Millward M, Francis RJ, et al: Final results of a phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). J Clin Oncol 28:523s, 2010 (suppl 15S; abstr 7036)
18. Kindler HL, Vogelzang NJ, Chien K, et al: SU5416 in malignant mesothelioma: A University of Chicago Phase II Consortium Study. Proc Am Soc Clin Oncol 20:43, 2001 (suppl; abstr 341a)
19. Baas P, Boogerd W, Dalesio O, et al: Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 48:291-296, 2005
20. Jahan TM, Gu L, Wang X, et al: Vatalanib in malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B (CALGB 30107). J Clin Oncol 24:384s, 2006 (suppl; abstr 7081)
21. Ferrara N, Hillan KJ, Gerber HP, et al: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400, 2004 (Pubitemid 38618122)
22. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
23. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
24. Brookmeyer R, Crowley J: A confidence interval for the median survival time. Biometrics 38:29-41, 1982
25. Cox DR: Regression models for life tables. J R Stat Soc B 34:187-202, 1972
26. Goldman AI: Issues in designing sequential stopping rules for monitoring side effects in clinical trials. Control Clin Trials 8:327-337, 1987
27. Herndon JE, Green MR, Chahinian AP, et al: Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113:723-731, 1998 (Pubitemid 28130949)
28. Curran D, Sahmoud T, Therasse P, et al: Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16:145-152, 1998 (Pubitemid 28041592)
29. Tsao AS, Wistuba I, Roth JA, et al: Malignant pleural mesothelioma. J Clin Oncol 27:2081-2090, 2009
30. Leighl NB, Bennouna J, Yi J, et al: Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. Br J Cancer 104:413-418, 2011
31. Sørensen HT, Mellemkjaer L, Olsen JH, et al: Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846-1850, 2000 (Pubitemid 32104130)
32. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
33. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004 (Pubitemid 38702844)
34. Sandler A, Gray R, Perry MC, et al: Paclitaxelcarboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
35. Rini BI, Halabo S, Rosenberg JE, et al: Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma. J Clin Oncol 26:5422-5428, 2008
36. Kindler HL, Niedzwiecki D, Hollis D, et al: Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28:3617-3622, 2010
37. Reck M, von Pawel J, Zatloukal P, et al: Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for non-squamous non-small-cell lung cancer: Results from a randomised phase III trial (AVAIL). Ann Oncol 21:1804-1809, 2010
38. Shaked Y, Henke E, Roodhart JM, et al: Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: Implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14:263-273, 2008
39. Zalcman G, Margery J, Scherpereel A, et al: IFCT-GFPC-0701 MAPS trial, a multicenter randomized phase II/III trial of pemetrexed-cisplatin with or without bevacizumab in patients with malignant pleural mesothelioma. J Clin Oncol 28:519s, 2010 (suppl 15S; abstr 7020)
40. Holden SN, Ryan S, Kearns A, et al: Benefit from bevacizumab is independent of pretreatment plasma vascular endothelial growth factor-A in patients with metastatic colorectal cancer. J Clin Oncol 23:159s, 2005 (suppl 17S; abstr 3555)
41. Cannistra SA: Phase II trials in Journal of Clinical Oncology. J Clin Oncol 27:3073-3076, 2009
42. Rubinstein LV, Korn EL, Freidlin B, et al: Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 23:7199-7206, 2005